An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Children With Acquired Immunodeficiency Syndrome (AIDS) Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine (Retrovir)

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Wallingford,
Connecticut06492

Purpose:

The purpose of this study is to make didanosine (ddI) available to children with AIDS who
are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the
Phase II ddI programs due to protocol exclusion or geographic location.

Criteria:

Inclusion Criteria
Concurrent Medication:
Allowed:
- Concomitant medications for the treatment of complications of AIDS.
- CAUTION:
- Concomitant use of ddI with the following drugs must be done with extreme caution:
- Other nucleosides (e.g., ganciclovir).
- Drugs with toxicities similar to those observed with ddI (e.g., phenytoin).
- Drugs with significant pancreatic toxicities, including many drugs used for treatment
of major opportunistic infections.
- Use of Sulfonamides or intravenous pentamidine for treatment of acute Pneumocystis
carinii pneumonia (PCP) requires discontinuation of ddI for a week following
treatment of PCP.
- Caution should also be exercised with patients having intractable diarrhea or
patients following a low sodium diet.
Patients must have the following:
- Diagnosis of AIDS. Demonstrated either significant deterioration despite parenteral
dosing with zidovudine (AZT) or significant intolerance to AZT.
Signed informed consent by parent or legal guardian. Evaluations every 7-14 days while
taking ddI for the first 4 months. Monthly follow-up is required thereafter.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Acute pancreatitis or any history of pancreatitis.
- Seizures or a history of seizure disorder.
- Grade I or greater peripheral neuropathy.
- Preexisting cardiomyopathy.
Concurrent Medication:
Excluded:
- Zidovudine (AZT).
- Chemotherapy with cytotoxic agents.
- AVOID:
- Those agents that may cause pancreatitis such as:
- Pentamidine.
- Sulfonamides.
- Antituberculosis drugs.
- Cimetidine.
- Ranitidine.
- Corticosteroids.
- NOTE the cautionary statement in Patient Inclusion Concurrent Medication.
Patients with the following are excluded:
- Acute pancreatitis or any history of pancreatitis.
- Seizures or a history of seizure disorder.
- Grade I or greater peripheral neuropathy.
- Preexisting cardiomyopathy.
Prior Medication:
Excluded within 15 days of study entry:
- Any anti-retroviral except zidovudine (AZT).
Required:
- Zidovudine (AZT).

NCT ID:

NCT00002280

Primary Contact:

Study DirectorBristol-Myers SquibbBristol-Myers Squibb

Backup Contact:

N/A

Location Contact:

Wallingford, Connecticut 06492United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: September 26, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.